Search research articles
Contact Us
Filters
Showing results (1-10 of 6) with videos related to
Page
of 1
Sort By:
The Journal of Clinical Psychiatry
|
January 2, 2007
Beneficial effects of prazosin for visual hallucinations associated with chronic cocaine abuse
Andre M Tapp, Annette Kennedy, Elaine R Peskind, et al.
The Annals of Pharmacotherapy
|
September 8, 2005
Antipsychotic polypharmacy: do benefits justify the risks?
Andre M Tapp, Amanda Ernst Wood, Nael Kilzieh, et al.
Alzheimer Disease and Associated Disorders
|
September 5, 2014
The utility of the Dementia Severity Rating Scale in differentiating mild cognitive impairment and Alzheimer disease from controls
Joel C Mitchell, Malcolm B Dick, Amanda E Wood, et al.
Journal of Clinical Psychopharmacology
|
January 22, 2008
Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting
Nael Kilzieh, Jeffrey A Todd-Stenberg, Annette Kennedy, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
May 20, 2006
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats
Murray A Raskind, Brianna L Burke, Norman J Crites, et al.
Journal of Addiction Medicine
|
July 20, 2011
Open trial of injectable risperidone for methamphetamine dependence
Charles W Meredith, Craig Jaffe, Monique Cherrier, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 6) with videos related to
Sort By:
Page
of 1
The Journal of Clinical Psychiatry
|
January 2, 2007
Beneficial effects of prazosin for visual hallucinations associated with chronic cocaine abuse
Andre M Tapp, Annette Kennedy, Elaine R Peskind, et al.
The Annals of Pharmacotherapy
|
September 8, 2005
Antipsychotic polypharmacy: do benefits justify the risks?
Andre M Tapp, Amanda Ernst Wood, Nael Kilzieh, et al.
Alzheimer Disease and Associated Disorders
|
September 5, 2014
The utility of the Dementia Severity Rating Scale in differentiating mild cognitive impairment and Alzheimer disease from controls
Joel C Mitchell, Malcolm B Dick, Amanda E Wood, et al.
Journal of Clinical Psychopharmacology
|
January 22, 2008
Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting
Nael Kilzieh, Jeffrey A Todd-Stenberg, Annette Kennedy, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|
May 20, 2006
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats
Murray A Raskind, Brianna L Burke, Norman J Crites, et al.
Journal of Addiction Medicine
|
July 20, 2011
Open trial of injectable risperidone for methamphetamine dependence
Charles W Meredith, Craig Jaffe, Monique Cherrier, et al.
Page
of 1